FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2052902333> ?p ?o ?g. }

• W2052902333 endingPage "131" @default.
• W2052902333 startingPage "124" @default.
• W2052902333 abstract "The aim of this study was to determine the characteristics of placebo effects in acute migraine treatment trials of triptans performed over 12 years and assess whether the use of placebo controls in trials of acute migraine treatment remains ethically and scientifically appropriate. We conducted a search for all controlled trials published in English between January 1991 and April 2002 in which adult subjects with migraine were randomly assigned to receive an oral triptan or placebo for the acute treatment of a migraine attack. Thirty-one trials met our criteria for inclusion. Placebo results for each study and pooled placebo results were calculated for the endpoints of headache response, pain-free response and adverse events. Heterogeneity was assessed using the Q statistic, and meta-regression using prespecified covariates was performed to investigate heterogeneity. The study results show a significant degree of heterogeneity. Efforts to explain heterogeneity with available data were not successful, with the exception of adverse event rates to placebo, for which study location (Europe vs. North America) partially explained differences in study results. AE rates were lower in European studies than in North American studies. Across all studies, the mean proportion of subjects who experienced a treatment response at two hours to placebo was 28.48 +/- 8.73% (range 17-50%). The mean proportion of subjects who experienced an adverse event to placebo was 23.40 +/- 14.05% (range 4.86-74%). The mean proportion of subjects who experienced a pain-free response to placebo at two hours was 6.08 +/- 4.43% (range 5-17%). Results of studies allowing use of prophylaxis did not differ significantly from those that did not allow prophylaxis. Placebo effects appear to be enhanced in studies involving children and adolescents. In contrast to an earlier, smaller review, our results do not suggest that randomization ratios influence placebo rates. We conclude that placebo effects in published trials of acute migraine medications are highly variable and often substantial. This variability in placebo response means that active control equivalence trials or the use of historical controls will not provide adequate proof of the safety or efficacy of new drugs, and will not differentiate between drugs that are active vs. placebo but of unknown efficacy relative to each other. The potential for approval of ineffective drugs, inability to compare results of studies performed in different locations, and poor characterization of the tolerability and safety profiles of new drugs represent a greater danger to migraineurs than does the limited-duration use of placebo in carefully monitored clinical trials of consenting subjects. These observations support the view that the inclusion of a placebo group remains of major scientific and ethical importance in trials of migraine medications." @default.
• W2052902333 created "2016-06-24" @default.
• W2052902333 creator A5039755607 @default.
• W2052902333 creator A5042860187 @default.
• W2052902333 creator A5047147554 @default.
• W2052902333 date "2005-02-01" @default.
• W2052902333 modified "2023-09-27" @default.
• W2052902333 title "Placebo Effects in Oral Triptan Trials: the Scientific and Ethical Rationale for Continued use of Placebo Controls" @default.
• W2052902333 cites W1966324558 @default.
• W2052902333 cites W1970105914 @default.
• W2052902333 cites W1970528604 @default.
• W2052902333 cites W1984136690 @default.
• W2052902333 cites W2001311112 @default.
• W2052902333 cites W2005537302 @default.
• W2052902333 cites W2006118174 @default.
• W2052902333 cites W2007812903 @default.
• W2052902333 cites W2017165238 @default.
• W2052902333 cites W2018834848 @default.
• W2052902333 cites W2025180868 @default.
• W2052902333 cites W2027261838 @default.
• W2052902333 cites W2028318581 @default.
• W2052902333 cites W2028665883 @default.
• W2052902333 cites W2039623332 @default.
• W2052902333 cites W2042800064 @default.
• W2052902333 cites W2045162596 @default.
• W2052902333 cites W2051450601 @default.
• W2052902333 cites W2059236456 @default.
• W2052902333 cites W2062795928 @default.
• W2052902333 cites W2068487066 @default.
• W2052902333 cites W2081808154 @default.
• W2052902333 cites W2088590171 @default.
• W2052902333 cites W2093816404 @default.
• W2052902333 cites W2096477929 @default.
• W2052902333 cites W2111937143 @default.
• W2052902333 cites W2114314315 @default.
• W2052902333 cites W2116593011 @default.
• W2052902333 cites W2122081700 @default.
• W2052902333 cites W2126194551 @default.
• W2052902333 cites W2132867515 @default.
• W2052902333 cites W2143800131 @default.
• W2052902333 cites W2147482899 @default.
• W2052902333 cites W2149133494 @default.
• W2052902333 cites W2150060517 @default.
• W2052902333 cites W2156939579 @default.
• W2052902333 cites W2158040075 @default.
• W2052902333 cites W2166530830 @default.
• W2052902333 cites W2167761850 @default.
• W2052902333 cites W2466674868 @default.
• W2052902333 cites W2506929947 @default.
• W2052902333 cites W2811193959 @default.
• W2052902333 cites W40967264 @default.
• W2052902333 cites W48338217 @default.
• W2052902333 doi "https://doi.org/10.1111/j.1468-2982.2004.00817.x" @default.
• W2052902333 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15658949" @default.
• W2052902333 hasPublicationYear "2005" @default.
• W2052902333 type Work @default.
• W2052902333 sameAs 2052902333 @default.
• W2052902333 citedByCount "75" @default.
• W2052902333 countsByYear W20529023332012 @default.
• W2052902333 countsByYear W20529023332013 @default.
• W2052902333 countsByYear W20529023332014 @default.
• W2052902333 countsByYear W20529023332015 @default.
• W2052902333 countsByYear W20529023332016 @default.
• W2052902333 countsByYear W20529023332017 @default.
• W2052902333 countsByYear W20529023332018 @default.
• W2052902333 countsByYear W20529023332019 @default.
• W2052902333 countsByYear W20529023332020 @default.
• W2052902333 countsByYear W20529023332021 @default.
• W2052902333 countsByYear W20529023332022 @default.
• W2052902333 countsByYear W20529023332023 @default.
• W2052902333 crossrefType "journal-article" @default.
• W2052902333 hasAuthorship W2052902333A5039755607 @default.
• W2052902333 hasAuthorship W2052902333A5042860187 @default.
• W2052902333 hasAuthorship W2052902333A5047147554 @default.
• W2052902333 hasConcept C126322002 @default.
• W2052902333 hasConcept C142724271 @default.
• W2052902333 hasConcept C170493617 @default.
• W2052902333 hasConcept C197934379 @default.
• W2052902333 hasConcept C204787440 @default.
• W2052902333 hasConcept C27081682 @default.
• W2052902333 hasConcept C2777119127 @default.
• W2052902333 hasConcept C2778541695 @default.
• W2052902333 hasConcept C2778871607 @default.
• W2052902333 hasConcept C2778938600 @default.
• W2052902333 hasConcept C2779085531 @default.
• W2052902333 hasConcept C2992459003 @default.
• W2052902333 hasConcept C42219234 @default.
• W2052902333 hasConcept C535046627 @default.
• W2052902333 hasConcept C71924100 @default.
• W2052902333 hasConceptScore W2052902333C126322002 @default.
• W2052902333 hasConceptScore W2052902333C142724271 @default.
• W2052902333 hasConceptScore W2052902333C170493617 @default.
• W2052902333 hasConceptScore W2052902333C197934379 @default.
• W2052902333 hasConceptScore W2052902333C204787440 @default.
• W2052902333 hasConceptScore W2052902333C27081682 @default.
• W2052902333 hasConceptScore W2052902333C2777119127 @default.
• W2052902333 hasConceptScore W2052902333C2778541695 @default.
• W2052902333 hasConceptScore W2052902333C2778871607 @default.

• next